Cbl Monoclonal Antibody

This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia, and expansion of CGG repeats in the 5' UTR has been associated with Jacobsen syndrome. Mutations in this gene are also the cause of Noonan syndrome-like disorder.

Introducing the CBL Monoclonal Antibody, a cutting-edge biotechnological product designed to revolutionize the field of immunology. This meticulously crafted antibody is derived from a single clone, ensuring utmost purity and consistency in its performance.

The CBL Monoclonal Antibody exhibits exceptional specificity, binding exclusively to the target antigen with unparalleled affinity. Its robust binding capability enables precise detection and quantification of the antigen, facilitating accurate diagnostic and research applications.

With its remarkable stability and long shelf life, the CBL Monoclonal Antibody guarantees reliable and reproducible results, making it an indispensable tool for laboratories and scientific institutions worldwide. Its versatility extends to various experimental techniques, including immunohistochemistry, flow cytometry, and Western blotting, enabling comprehensive analysis of complex biological systems.

Furthermore, the CBL Monoclonal Antibody is manufactured under stringent quality control measures, adhering to the highest industry standards. Each batch undergoes rigorous testing to ensure optimal performance, consistency, and safety.

In summary, the CBL Monoclonal Antibody represents a breakthrough in immunological research, offering unrivaled specificity, stability, and versatility. Embrace this innovative product and unlock new possibilities in your scientific endeavors.